利福昔明治疗肝硬化的研究进展

Research progress of rifaximin in the treatment of cirrhosis

肝硬化是慢性肝病的一种晚期表现,近年来针对肝硬化的治疗取得了显著进展,以控制症状和并发症发生为主要目标。利福昔明是一种胃肠道吸收极少的抗生素,它可以通过影响肠道微生物群及肠-肝轴等干预肝硬化进程。利福昔明治疗肝硬化及其并发症的疗效得到了越来越多的研究,本文就利福昔明治疗肝硬化的研究进展进行综述,以更好地指导临床用药。

Cirrhosis is an advanced manifestation of chronic liver disease.In recent years,significant progress has been made in the treatment of cirrhosis,with the main goal being to control symptoms and complications.Rifaximin,an antibiotic with minimal gastrointestinal absorption,can interfere with the progression of cirrhosis by affecting the intestinal microbiota and the enterohepatic axis.More and more studies have been conducted on the efficacy of rifaximin in the treatment of cirrhosis and its complications.This article reviewed the research progress of rifaximin in the treatment of cirrhosis,so as to better guide clinical medication.